Editorial Commentary: Ceftazidime-Avibactam and Carbapenem-Resistant Enterobacteriaceae: "We're Gonna Need a Bigger Boat"

Clinical Infectious Diseases

Volumn 63, Issue 12, 2016, Pages 1619-1621

  Spellberg, Brad ^a,b   Bonomo, Robert A ^c  

^a LAC USC MEDICAL CENTER   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

antibiotic resistance; carbapenem resistance; ceftazidime avibactam; CRE; Enterobacteriaceae

Indexed keywords

ANTIINFECTIVE AGENT; AVIBACTAM, CEFTAZIDIME DRUG COMBINATION; AZABICYCLO DERIVATIVE; BETA LACTAMASE; CEFTAZIDIME;

CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTION; MICROBIAL SENSITIVITY TEST; SHIP;

ANTI-BACTERIAL AGENTS; AZABICYCLO COMPOUNDS; BETA-LACTAMASES; CARBAPENEM-RESISTANT ENTEROBACTERIACEAE; CEFTAZIDIME; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; MICROBIAL SENSITIVITY TESTS; SHIPS;

EID: 85051212083     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw639     Document Type: Note

References (22)

1. Spellberg B, Shlaes D. Prioritized current unmet needs for antibacterial therapies. Clin Pharmacol Ther 2014; 96:151-3.
2. Antibiotic resistant threats in the United States, 2013. US Centers for Disease Control and Prevention. Available at: Http://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf. Accessed 15 August 2016.
3. Infectious Diseases Society of America. White Paper. Recommendations on the conduct of superiority and organism-specific clinical trials of antibacterial agents for the treatment of infections caused by drug-resistant bacterial pathogens. Clin Infect Dis 2012; 55:1031-46.
4. Gasink LB, Edelstein PH, Lautenbach E, Synnestvedt M, Fishman NO. Risk factors and clinical impact of Klebsiella pneumoniae carbapenemaseproducing K. pneumoniae. Infect Control Hosp Epidemiol 2009; 30:1180-5.
5. Schwaber MJ, Carmeli Y. Mortality and delay in effective therapy associated with extendedspectrum beta-lactamase production in Enterobacteriaceae bacteraemia: A systematic review and meta-analysis. J Antimicrob Chemother 2007; 60:913-20.
6. Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29:1099-106.
7. Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011; 12:1798-803.
8. Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: A call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008; 46:155-64.
9. Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. N Engl J Med 2013; 368:299-302.
10. Spellberg B, Blaser M, Guidos R, et al. Combating antimicrobial resistance: Policy recommendations to save lives. Clin Infect Dis 2011; 52(suppl 5): S397-428.
11. Drawz SM, Papp-Wallace KM, Bonomo RA. New beta-lactamase inhibitors: A therapeutic renaissance in an MDR world. Antimicrob Agents Chemother 2014; 58:1835-46.
12. van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: Second-generation beta-lactam/beta-lactamase inhibitor combinations. Clin Infect Dis 2016; 63:234-41.
13. Rice LB, Eckstein EC, DeVente J, Shlaes DM. Ceftazidime-resistant Klebsiella pneumoniae isolates recovered at the Cleveland Department of Veterans Affairs Medical Center. Clin Infect Dis 1996; 23:118-24.
14. Hujer AM, Hujer KM, Helfand MS, Anderson VE, Bonomo RA. Amino acid substitutions at Ambler position Gly238 in the SHV-1 beta-lactamase: Exploring sequence requirements for resistance to penicillins and cephalosporins. Antimicrob Agents Chemother 2002; 46:3971-7.
15. Mazuski JE, Gasink LB, Armstrong J, et al. Efficacy and safety of ceftazidime-avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infection: Results from a randomized, controlled, doubleblind, phase 3 program. Clin Infect Dis 2016; 62:1380-9.
16. Wagenlehner FM, Sobel JD, Newell P, et al. Ceftazidime- A vibactam versus doripenem for the treatment of complicated urinary tract infections, including acute pyelonephritis: RECAPTURE, a phase 3 randomized trial program. Clin Infect Dis 2016; 63:754-62.
17. Winkler ML, Papp-Wallace KM, Bonomo RA. Activity of ceftazidime/avibactam against isogenic strains of Escherichia coli containing KPC and SHV beta-lactamases with single amino acid substitutions in the omega-loop. J Antimicrob Chemother 2015; 70:2279-86.
18. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of aminoglycoside and beta-lactam combination therapy versus betalactam monotherapy on the emergence of antimicrobial resistance: A meta-analysis of randomized, controlled trials. Clin Infect Dis 2005; 41:149-58.
19. Paul M, Lador A, Grozinsky-Glasberg S, Leibovici L. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. Cochrane Database Syst Rev 2014:CD003344.
20. Johnson AS. Annual oration: Medicine's responsibility in the propagation of poor protoplasm. N Engl J Med 1948; 238:755-8.
21. Burnet M. Natural history of infectious disease. Cambridge, England: Cambridge University Press, 1962.
22. Petersdorf RG. Whither infectious diseases Memories, manpower, and money. J Infect Dis 1986; 153:189-95.